U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

FEVIPIPRANT

MORE DETAILS

  2PEX5N7DQ4

Status:
Investigational
Source:
NCT03681093: Phase 3 Interventional Completed Nasal Polyps
(2019)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT03681093
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Prostaglandin D2 receptor 2
3
Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.

4-AMINO-2-(TRIFLUOROMETHYL)BENZONITRILE

MORE DETAILS

L47D9XHC08

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)

4-CHLORO-3-(TRIFLUOROMETHYL)ANILINE

MORE DETAILS

000N5814MR

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966